Original research articleMidtrimester medical termination of pregnancy: a review of 1002 consecutive cases
Introduction
Dilatation and evacuation (D&E) of the uterus is the favored method for second-trimester termination of pregnancy in the United States and in the non-National Health Service (NHS) abortion sector in the United Kingdom, whereas within the NHS sector, medical methods are used predominantly [1]. D&E is safe and effective but can only be performed by gynecologists who are skilled in the technique [2], [3]. Between 1988 and 1996 there were nine maternal deaths in the United Kingdom related to legal abortion, of which five followed midtrimester abortion and three of these were following D&E of the uterus. A previous report on confidential inquiries into maternal deaths in the United Kingdom questioned the appropriateness of D&E as a method of terminating second-trimester pregnancy when safe and effective medical alternatives exist [4].
Medical induction of abortion using the prostaglandin (PG)E1 analogues, gemeprost or misoprostol alone, is efficient, although the mean induction-to-abortion interval can be as long as 12–16 h [5], [6]. Pretreatment with the antiprogesterone mifepristone, prior to prostaglandin administration, reduces the induction-to-abortion interval, as well as the analgesia requirements and the total dose of prostaglandin required [7], [8], [9]. In the UK, mifepristone in a 600-mg dose in combination with the prostaglandin E1 analogue, gemeprost, has been licensed for midtrimester medical abortion since 1995 and is increasingly used at all gestations [10], [11], [12]. However, randomized studies have indicated that a reduced dose of 200 mg of mifepristone is equally effective for termination of pregnancy in the second trimester [13], [14]. Similarly the prostaglandin E1 analogue, misoprostol, has been shown to be an effective alternative to gemeprost [15], [16], [17]. Moreover, it can be administered orally or vaginally and does not require special storage conditions [18].
This series of 1002 cases is a continuum to our previously reported experience [19], with the regimen comprising 200 mg mifepristone in combination with misoprostol. The aim of this study was to assess the factors affecting the outcome of midtrimester medical abortion in addition to assessing the effectiveness and safety of this regimen in clinical practice from one teaching hospital over an 8-year period.
Section snippets
Materials and methods
This report is based on a consecutive series of 1002 women with pregnancies between 13 and 21 weeks of amenorrhea undergoing induced abortion under the terms of the 1967 Abortion Act in one Scottish NHS hospital between May 1994 and November 2001. Women presenting beyond 13 weeks gestation were offered only medical termination of pregnancy (the regimen reported here). Women who presented with a previous cesarean section were offered the same regimen. Termination of pregnancy was not offered
Results
A total of 1002 women had medical midtrimester termination of pregnancy during the period May 1994 to November 2001. All data were prospectively collected.
Discussion
This study is the largest reported series evaluating the effectiveness of medical abortion in routine clinical practice in the second trimester using mifepristone and misoprostol. The effectiveness of the regimen is at least as, if not more, effective as the regimen using mifepristone and gemeprost. Tang et al. reviewed 956 women undergoing medical abortion in a single center using mifepristone and gemeprost and showed that 68.6% aborted within 10 h of prostaglandin administration and were
Acknowledgements
Study conducted at, and financial support provided by, the Department of Obstetrics and Gynecology, University of Aberdeen, Aberdeen, UK.
References (25)
- et al.
Termination of pregnancy at 9–13 weeks' amenorrhoea with mifepristone and misoprostol
Lancet
(1998) - et al.
Second trimester medical abortion with mifepristone and gemeprosta review of 956 cases
Contraception
(2001) - et al.
Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancy
Obstet Gynecol
(1997) - Royal College of Obstetricians and Gynaecologists Guideline No. 11, 1997. Induced...
- et al.
Complications from legally-induced abortiona review
Obstet Gynecol Surv
(1979) - et al.
Second-trimester abortion by dilatation and evacuationan analysis of 11,747 cases
Obstet Gynecol
(1983) - Report of Confidential Enquiries into Maternal Deaths in the United Kingdom 1994–1996. “Why mothers die.” Department of...
- et al.
A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy
N Engl J Med
(1994) - et al.
An open study comparing two regimens of gemeprost for the termination of pregnancy in the second trimester
Acta Obstet Gynecol Scand
(1992) - et al.
Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion
Br J Obstet Gynaecol
(1990)
Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy
Hum Reprod
The use of mifepristone prior to prostaglandin-induced midtrimester abortion
Hum Reprod
Cited by (144)
Abortion medical management between 14−16 weeks’ amenorrhea after French legislation deadline extension
2024, Journal of Gynecology Obstetrics and Human ReproductionSociety of Family Planning Clinical Recommendation: Medication abortion between 14 0/7 and 27 6/7 weeks of gestation: Jointly developed with the Society for Maternal-Fetal Medicine
2023, American Journal of Obstetrics and GynecologyMedical strategy for abortions between 14 and 16 weeks of gestation
2022, Gynecologie Obstetrique Fertilite et SenologieMifepristone-Misoprostol Use for Second- and Third-Trimester Medical Termination of Pregnancy in a Canadian Tertiary Care Centre
2022, Journal of Obstetrics and Gynaecology Canada